Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 3Withdrawn 2Recruiting 2Not yet recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 369Neoplasms 253Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 192Lung Neoplasms 140Colorectal Neoplasms 137Neoplasm Metastasis 132Pancreatic Neoplasms 131Leukemia, Myeloid, Acute 126Multiple Myeloma 122Lymphoma 114Carcinoma, Hepatocellular 111Ovarian Neoplasms 98Melanoma 97Recurrence 93Leukemia 88Head and Neck Neoplasms 88Leukemia, Lymphocytic, Chronic, B-Cell 86Brain Neoplasms 86Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Glioblastoma 77Lymphoma, Non-Hodgkin 73Squamous Cell Carcinoma of Head and Neck 71Lymphoma, Follicular 70Lymphoma, Large B-Cell, Diffuse 66Colonic Neoplasms 66Carcinoma, Renal Cell 61Hematologic Neoplasms 59Sarcoma 55Glioma 53

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Interventional × CRC × Clear all
NCT07511972 2026-04-06

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NGM Biopharmaceuticals, Inc

Phase 2 Withdrawn

CRC

NCT03337776 2021-08-05

Effect of WhatsApp Messenger on Uptake of CRC Screening Study

Chinese University of Hong Kong

Phase NA Withdrawn

CRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡